title: Regenerative therapy in peripheral artery disease.
abstract: Patients with peripheral artery disease (PAD) and critical limb ischemia are the main candidates for limb amputations and have a poor life expectancy. Frequently, these patients are not eligible for either surgical or percutaneous interventions aimed at mechanical revascularization. Therefore, new strategies need to be identified to offer these patients a viable therapeutic option. Gene and cell therapy hold great promise for the treatment of peripheral vascular diseases because, in animal models, local delivery of growth factors and endothelial progenitor cells result in new blood vessel formation and regeneration of ischemic tissues. In this article, are reviewed phase I and phase II gene, and cell therapy clinical trials in patients with PAD.
authors.affiliation: Fondazione Livio Patrizi, Rome, Italy. a.germani@fondazioneliviopatrizi.com
authors.forename: Antonia
authors.initials: A
authors.lastname: Germani
authors.forename: Cristiana
authors.initials: C
authors.lastname: Di Campli
authors.forename: Giulio
authors.initials: G
authors.lastname: Pompilio
authors.forename: Paolo
authors.initials: P
authors.lastname: Biglioli
authors.forename: Maurizio C
authors.initials: MC
authors.lastname: Capogrossi
mesh_terms: D016026:Bone Marrow Transplantation; D064987:Cell- and Tissue-Based Therapy; D016220:Fibroblast Growth Factor 1 / Q000235:genetics; D015316:Genetic Therapy; D017228:Hepatocyte Growth Factor / Q000235:genetics; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000235:genetics; D007963:Leukocytes, Mononuclear / Q000637:transplantation; D016491:Peripheral Vascular Diseases / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics
chemical_list: C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D042461:Vascular Endothelial Growth Factor A; D016220:Fibroblast Growth Factor 1; D017228:Hepatocyte Growth Factor